SunPower Corporation (NASDAQ:SPWR), the maker of solar systems cut its fiscal year 2015 outlook to below the consensus. SPWR is moving closer to the low end of the 52-week range of $25.38-$42.07. The company now expects non-GAAP revenue of $2.4 billion to $2.6 billion, gross margin of 21% to 23% and net income per diluted share of $1.10 to $1.50, below the consensus of $1.65 per share on revenues of $2.82 billion.SunPower Corporation (NASDAQ:SPWR) also updated its Q4 2014 GAAP financial outlook to include $450 million in revenue and $0.80-$0.90 in EPS related to its 579-MW solar star projects. SPWR expects Q4 GAAP revenue of $1.12 billion to $1.17 billion, gross margin of 26% to 28% and net income per diluted share of $1.00 to $1.25 compared to a previous outlook of $675 million to $725 million in sales, EPS of $0.20 to $0.35 and gross margin of 22%-24%. The company reiterated its Q4 non-GAAP guidance, with revenue of $575 million to $625 million, gross margin of 19% to 21%, and net income per diluted share of $0.15 to $0.30. The Street stands at $608.5 million in revenue for Q4 and earnings of $0.24 per share.Click here for a free comprehensive Trend Analysis ReportNewtek Business Services, Inc (NASDAQ:NEWT), the provider of business services and financial products for small- and medium-sized businesses said its offering of 2.2 million shares of common stock--up from the 2 million it initially planned to offer--priced at $12.50 per share, a 1.2% discount to the stock's Wednesday closing price. Newtek Business Services, Inc (NASDAQ:NEWT) is trading near the low end of its 52-week range of $11.30 to $17.15.In connection with the offering, the company has granted the underwriters for the offering an option to purchase up to an additional 330,000 shares of its common stock. Earlier this month, the company had expected the overallotment option to consist of 300,000 additional shares. Prior to the pricing of the offering, Newtek Business Services Inc. merged into Newtek Business Services Corp. and filed an election to be regulated as a business-development company. It intends to use the net proceeds of the offering to expand its financing activities and to primarily increase its activity in SBA 7(a) lending and make direct investments in portfolio companies in accordance with its investment objectives and strategies.Click here for a free comprehensive Trend Analysis ReportAastrom Biosciences Inc (NASDAQ:ASTM), a developer of cellular therapies, announced Q3 results that reported a wider Q3 loss from the same period a year ago despite revenues that exceeded expectations. The company reported a Q3 loss of $0.52, wider than the loss of $0.06 reported in Q3 2013 but less than the loss of $0.66 expected by analysts. Total revenues of $9.65 million were up from no revenues reported a year ago and topped analyst projections of $6.73 million. Research and development expenses for the quarter were $7.8 million, up from $2.6 million for the same period a year ago. Shares of Aastrom Biosciences Inc (NASDAQ:ASTM) are trading within a 52-week range of $2.55 - $7.00.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
